Don Dizon, MD, on Creating a Gender-Affirming Environment for Transgender Patients With Cancer

Video

Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.

In an interview with CancerNetwork®, Don Dizon, MD, FACP, FASCO, director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, explained how providers can create a more welcoming environment for transgender patients with cancer. He said that mission statements supporting this patient population and physical infrastructure choices such as gender-neutral bathrooms and magazine choices can be helpful in making transgender men, lesbian women, and cisgender men feel comfortable in breast cancer clinics.

Transcript:

Several things can be done to physical infrastructure, and certainly to mission statements. Those are easier to do than others. Having a mission statement that espouses a quality that really reaffirms sexual orientation as a human right, that affirms gender as a human right that is to be respected and not maligned [is important]. Then looking at your waiting areas, seeing that there are bathrooms for men, for women, and one that's not labeled [is also worth considering]. Having diversity of your magazines in your waiting area [can also create a welcoming environment]. It shouldn't all be Cosmopolitan and Time magazine. Some of them should be gender neutral [and not] speak to men or women. You [need to] think of the physical infrastructure—the feng shui of your place—and you want to see that anyone who walks into this area is welcome. This is the biggest issue regarding women's cancer centers. The Center for Women's Oncology or the Center for Breast Cancer Care, all adorned in pink, all adorned with female imagery, all adorned with female breasts, is not necessarily going to be that welcoming to the transgender male who has breast cancer, or the lesbian who has breast cancer, and all she sees are heterosexual partners. But it's also not going to be welcoming to men with breast cancer either.

Recent Videos
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Related Content